TAI’AN, China, Sept. 16, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO, “China Biologic” or the “Company”), a leading plasma-based biopharmaceutical company in China, today announced that it will present at the UBS Global Life Sciences Conference in New York on September 19.
Mr. Tristan Kuo, China Biologic’s Chief Financial Officer, will present at the conference on Monday, September 19, 2011 at 2:00 p.m. in the Grand Hyatt New York, 109 East 42nd Street at Grand Central Terminal, New York, NY.
Institutional investors interested in meeting with Mr. Kuo during the conference should please contact their UBS sales representative.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd., and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi’an Huitian Blood Products Co., Ltd., is currently one of the leading plasma-based biopharmaceutical companies in China.
China Biologic is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company’s plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company’s website at www.chinabiologic.com for additional information.
Company Contact | |
Mr. Y. Tristan Kuo | |
Chief Financial Officer | |
China Biologic Products, Inc. | |
Tel: +86 53 8620 2206 | |
Email: IR@chinabiologic.com | |
SOURCE China Biologic Products, Inc.
